Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients

Reuters

08/30

Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients

Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2563113885"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563113885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563113885?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-30 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563113885","market":"nz","top_or_hot":-1,"title":"Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-30 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250830:nNDL3BrCN4:1","article_id":"2563113885","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563113885","pubTimestamp":1756557014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amarin Corporation Announces New REDUCE-IT Analyses Showing VASCEPA/VAZKEPA Therapy Reduces Cardiovascular Risk in High-Risk Patients. Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA/VAZKEPA  on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","AMRN":"阿玛琳","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Amarin Corporation宣布推出新的REDUCE-IT®分析显示VASCEPA®/瓦兹凯帕®治疗降低高危患者的心血管风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":0.9,"NDAQ":0.9},"content_text":"Amarin Corporation Announces New REDUCE-IT® Analyses Showing VASCEPA®/VAZKEPA® Therapy Reduces Cardiovascular Risk in High-Risk Patients\n    \n\n        Amarin Corporation plc has announced new analyses from the REDUCE-IT trial, highlighting the impact of VASCEPA®/VAZKEPA® (icosapent ethyl) on cardiovascular disease risk. The data, presented at the European Society of Cardiology Congress 2025, reveals that this therapy resulted in a 9% reduction in total hospitalizations and decreased cardiovascular disease risk in certain high-risk patient subgroups. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Focused Update has reaffirmed high-dose icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients. The guideline emphasizes its use in patients with elevated triglyceride levels despite statin therapy, to lower cardiovascular events.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520815-en) on August 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}